Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasm, Residual

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

This study includes a total of 60 multiple myeloma patients, and peripheral blood will be collected at newly diagnosed, remission after 4 cycles of therapy, and, relapse stage.

10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.

plasma circulation DNA methylation sequencing

Gang An, PhD

Jian Cui, Bachelor

Gang An, PhD&MD

InsituteHBDH

1. To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods for MM;
2. Carry out ctDNA-based methylation sequencing in newly diagnosed, remission, and, relapsed MM patients, to track the clonal evolution patterns; and explore the in the initial diagnosis-remission-relapse stage of MM, track the clonal evolution characteristics of methylation profiles in MM patients during the disease progression.

ctDNA Methylation Sequencing for Myeloma

Circulating Tumor DNA Methylation Sequencing for Multiple Myeloma Minimal Residual Disease Detection and Clonal Evolution Monitoring

The datasets generated during and/or analysed during the current study are available from the corresponding author at angang@ihcams.ac.cn on reasonable request.

When the peripheral blood samples required for the study have been collected

MethylGene Tech Co., Ltd. China

Institute of Hematology & Blood Diseases Hospital, China

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
ctDNA Methylation Sequencing for Myeloma	NCT05578625	Multiple Myelom...	plasma circulat...	18 Years - 75 Years	Institute of Hematology & Blood Diseases Hospital, China
ctDNA Methylation Sequencing for Myeloma	NCT05578625	Multiple Myelom...	plasma circulat...	18 Years - 75 Years	Institute of Hematology & Blood Diseases Hospital, China

Spots Global Cancer Trial Database for circulationg tumor dna